UK markets close in 5 hours 46 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
68.81-0.19 (-0.28%)
At close: 4:00PM EDT

68.88 +0.07 (0.10%)
Before hours: 5:33AM EDT

Full screen
Trade prices are not sourced from all markets
Previous close69.00
Open69.02
Bid0.00 x 2200
Ask69.47 x 1200
Day's range68.62 - 69.61
52-week range60.89 - 85.97
Volume7,980,946
Avg. volume9,953,084
Market cap86.313B
Beta (5Y monthly)0.66
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.72 (3.94%)
Ex-dividend date14 Sep 2020
1y target estN/A
  • Diodes Incorporated Reports Second Quarter 2020 Financial Results
    Business Wire

    Diodes Incorporated Reports Second Quarter 2020 Financial Results

    Diodes Incorporated (Nasdaq: DIOD) today reported its financial results for the second quarter ended June 30, 2020.

  • State attorneys general urge U.S. to let other firms make Gilead COVID-19 drug
    Reuters

    State attorneys general urge U.S. to let other firms make Gilead COVID-19 drug

    The coalition of more than 30 state attorneys general called on the government to act or allow states to do so, saying in a letter to U.S. health agencies that Gilead "has not established a reasonable price" for remdesivir. "Gilead should not profit from the pandemic and it should be pushed to do more to help more people," the letter said.

  • Is Gilead Sciences a Buy After Its Disappointing Q2 Results?
    Motley Fool

    Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

    Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. Last week, Gilead announced second-quarter results that were below analysts' expectations. Gilead has been in the news quite a bit in recent months thanks to the clinical success for its COVID-19 therapy remdesivir.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more